ADMA Biologics Revenue and Competitors

Ramsey, NJ USA

Location

$547.4M

Total Funding

Biotech

Industry

Estimated Revenue & Valuation

  • ADMA Biologics's estimated annual revenue is currently $82.2M per year.(i)
  • ADMA Biologics received $41.9M in venture funding in November 2017.
  • ADMA Biologics's estimated revenue per employee is $217,000
  • ADMA Biologics's total funding is $547.4M.

Employee Data

  • ADMA Biologics has 379 Employees.(i)
  • ADMA Biologics grew their employee count by 6% last year.

ADMA Biologics's People

NameTitleEmail/Phone
Competitor NameRevenueNumber of EmployeesEmployee GrowthTotal FundingValuation
#1
$8.5M55-21%N/AN/A
#2
$0.2M10%N/AN/A
#3
$8.5M55-29%N/AN/A
#4
$108.5M5002%N/AN/A
#5
$0.8M50%N/AN/A
#6
$0.6M40%N/AN/A
#7
$14.7M68-23%$206.4MN/A
#8
$492.2M1503-15%$568MN/A
#9
$1.1M7-42%N/AN/A
#10
$4.5M290%N/AN/A
Add Company

What Is ADMA Biologics?

ADMA is a late-stage biopharmaceutical company that develops, manufactures and intends to commercialize specialty plasma-based biologics for the treatment and prevention of Primary Immune Deficiency Disease (PIDD) and certain infectious diseases. ADMA's mission is to develop and commercialize plasma-derived, human immune globulins targeted to niche patient populations for the treatment and prevention of certain infectious diseases. The target patient populations include immune-compromised individuals who suffer from an underlying immune deficiency disease, or who may be immune-compromised for medical reasons. ADMA's lead product candidate, RI-002, has completed a Phase III clinical trial in patients with PIDD and has met the primary endpoint. A BLA for RI-002 was accepted by the FDA on September 18, 2015. The company has received U.S. Patent 9,107,906. For more information, please visit the company's website at www.admabiologics.com.

keywords:Biotechnology,Healthcare,Pharmaceuticals

$547.4M

Total Funding

379

Number of Employees

$82.2M

Revenue (est)

6%

Employee Growth %

N/A

Valuation

N/A

Accelerator

ADMA Biologics News

2022-04-20 - Short Interest in ADMA Biologics, Inc. (NASDAQ:ADMA ...

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the...

2022-03-22 - ADMA Biologics to Report Fourth Quarter and Full Year 2021 ...

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-...

2022-03-22 - ADMA Biologics Announces FDA Approval of Extended Shelf ...

ADMA Biologics is an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-...

2021-11-11 - ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments - Form 8-K

ADMA Biologics Reports Record Third Quarter 2021 Financial Results and Highlights Recent Progress and Accomplishments Generated Record Total Revenues of $20.7 Million in the Third Quarter 2021, a 101% Increase Over Third Quarter 2020 Achieved First-Time Positive Gross Profit Narrowed Net Loss ...

2021-10-25 - ADMA Biologics : Announces Closing of $57.5 Million Public Offering Including Full Exercise of Underwriters' Option to Purchase Additional Shares

RAMSEY, N.J. and BOCA RATON, Fla., Oct. 25, 2021 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing and developing specialty plasma-derived biologics, today announced the closing of its previously anno ...

Company NameRevenueNumber of EmployeesEmployee GrowthTotal Funding
#1
$86.4M4610%N/A
#2
$150.7M4923%N/A
#3
N/A562N/AN/A
#4
$126.7M563N/AN/A
#5
$243.4M590-2%N/A

ADMA Biologics Funding

DateAmountRoundLead InvestorsReference
2014-12-16$5.0MUndisclosedHercules Technology Growth Capital, IncArticle
2015-03-19$10.3MUndisclosedRaymond JamesArticle
2015-06-23$21.0MUndisclosedOxford FinanceArticle
2017-11-10$41.9MUndisclosedRaymond James & Associates, IncArticle